Drug profile · INN
daratumumab and hyaluronidase-fihj
DARZALEX FASPRO
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
daratumumab and hyaluronidase-fihj (DARZALEX FASPRO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
Key facts
INN daratumumab and hyaluronidase-fihj
Brand DARZALEX FASPRO
Route INJECTION
Formulation INJECTABLE
Frequently asked questions
What is daratumumab and hyaluronidase-fihj?
daratumumab and hyaluronidase-fihj (DARZALEX FASPRO) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for daratumumab and hyaluronidase-fihj?
DARZALEX FASPRO is a marketed brand name for daratumumab and hyaluronidase-fihj. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of daratumumab and hyaluronidase-fihj?
daratumumab and hyaluronidase-fihj has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.